New combo therapy shows promise for First-Line CLL treatment
NCT ID NCT03609593
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested a combination of bendamustine and rituximab (BR) followed by venetoclax in 42 people with untreated chronic lymphocytic leukemia (CLL). The goal was to see how many patients responded to the full 15-month treatment. Venetoclax is an oral drug that targets a protein on CLL cells, but it can cause a dangerous side effect called tumor lysis syndrome, so dosing was carefully stepped up.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bendamustine, rituximab, and venetoclax
What this could lead to
If successful, this combination could offer a more effective first-line treatment for chronic lymphocytic leukemia, potentially leading to longer remission without needing continuous therapy.
What could go wrong
This is a small, single-arm phase 2 trial with only 42 participants, so results may not apply to all patients. There is a risk of tumor lysis syndrome, a serious side effect from rapid cell destruction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, 10032, United States